Literature DB >> 7954398

Relationship between the structure of taxol and other taxanes on induction of tumor necrosis factor-alpha gene expression and cytotoxicity.

C A Burkhart1, J W Berman, C S Swindell, S B Horwitz.   

Abstract

Taxol is an antitumor drug with cytotoxic properties that correlate with its microtubule-stabilizing activities. It has been reported that taxol parallels lipopolysaccharide in its effects on the induction of tumor necrosis factor-alpha (TNF-alpha) gene expression in macrophages (C. Bogdan and A. Ding, J. Leukocyte Biol., 52: 119-121, 1992; C. L. Manthey, M. E. Brandes, P. Y. Perera, and S. Vogel, J. Immunol., 149: 2459-2465, 1992; J. M. Carboni, C. Singh, and M. A. Tepper, Natl. Cancer Inst. Monogr., 15: 95-101, 1993). Structure-activity studies using taxol and related taxanes have been done to determine the relationship between the effects of taxol on TNF-alpha gene expression and its cytotoxic and microtubule-stabilizing activities. Using Northern blot analysis, it was found that changes in the structure of taxol that did not alter cytotoxicity did prevent the induction of TNF-alpha gene expression. The data presented in this paper demonstrate that the effects of taxol on TNF-alpha gene expression are distinct from its known cytotoxic properties.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7954398

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

Review 1.  Tubulin interacting agents: novel taxanes and epothilones.

Authors:  Neeraj R Agrawal; Ram Ganapathi; Tarek Mekhail
Journal:  Curr Oncol Rep       Date:  2003-03       Impact factor: 5.075

2.  Identification of tumor-specific paclitaxel (Taxol)-responsive regulatory elements in the interleukin-8 promoter.

Authors:  L F Lee; J S Haskill; N Mukaida; K Matsushima; J P Ting
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

3.  p53-independent apoptosis induced by paclitaxel through an indirect mechanism.

Authors:  J S Lanni; S W Lowe; E J Licitra; J O Liu; T Jacks
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

4.  Heat shock protein 90 mediates macrophage activation by Taxol and bacterial lipopolysaccharide.

Authors:  C A Byrd; W Bornmann; H Erdjument-Bromage; P Tempst; N Pavletich; N Rosen; C F Nathan; A Ding
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

Review 5.  Paclitaxel chemotherapy for the treatment of gastric cancer.

Authors:  Junichi Sakamoto; Takanori Matsui; Yasuhiro Kodera
Journal:  Gastric Cancer       Date:  2009-06-27       Impact factor: 7.370

6.  Targeting myeloid regulatory cells in cancer by chemotherapeutic agents.

Authors:  Hiam Naiditch; Michael R Shurin; Galina V Shurin
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

7.  A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers.

Authors:  Krithika N Kodumudi; Karrune Woan; Danielle L Gilvary; Eva Sahakian; Sheng Wei; Julie Y Djeu
Journal:  Clin Cancer Res       Date:  2010-08-11       Impact factor: 12.531

8.  Identification of novel formyl peptide receptor-like 1 agonists that induce macrophage tumor necrosis factor alpha production.

Authors:  Igor A Schepetkin; Liliya N Kirpotina; Jun Tian; Andrei I Khlebnikov; Richard D Ye; Mark T Quinn
Journal:  Mol Pharmacol       Date:  2008-05-05       Impact factor: 4.436

9.  Computational structure-activity relationship analysis of non-peptide inducers of macrophage tumor necrosis factor-alpha production.

Authors:  Andrei I Khlebnikov; Igor A Schepetkin; Liliya N Kirpotina; Mark T Quinn
Journal:  Bioorg Med Chem       Date:  2008-09-05       Impact factor: 3.641

10.  Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement.

Authors:  Charlie T Garnett; Jeffrey Schlom; James W Hodge
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.